Regenerative Medicine Center seeks to advance stem cell research. !--h2>
Pfizer launched an independent research unit known as Pfizer Regenerative Medicine. The unit, led by CSO, Ruth McKernan, Ph.D., is expected to employ around 70 researchers and will build on recent scientific progress in understanding the biology of stem cells. The scientists will operate in small, flexible teams, with the capability to make decisions quickly and effectively.
Researchers at Pfizer Regenerative Medicine will explore the use of stem cells to develop future treatments that may prevent disability, repair failing organs, and treat degenerative diseases. The ultimate goal will be to deliver new medicinal products that can pave the way for the use of cells as therapeutics.
Pfizer Regenerative Medicine will be co-located in the biotech hubs of Cambridge, U.K., and Cambridge, MA, in the U.S. The U.K. unit will focus on neural and sensory disorders, and the U.S. site on endocrine and cardiac research.